Share |

Content about Pharmaceutical industry

August 25, 2011

No one knows more about wasteful spending than the government, and healthcare is on top of most people’s list when it comes to wasteful spending. Since 2009 the focus has shifted towards bringing down the cost of healthcare spending.

August 24, 2011

One of the largest and most profitable biotechnology companies in the Mid-Atlantic is trying to increase its revenue by developing an oral form of treatment for pulmonary arterial hypertension (PAH).

Silver Spring-based United Therapeutics Corporation (NASDAQ: UTHR) released its FREEDOM-C(2) Phase 3 clinical trial results today but the company announced that the study did not meet its primary endpoint.

August 16, 2011

Rockville-based Nabi Biopharmaceuticals (Nasdaq:NABI) has added to its cash stockpile by obtaining $5 Million in milestone payments from Fresenius USA Manufacturing, Inc.

August 9, 2011

The company has partnered with Teva Pharmaceutical Industries of Israel to develop Multikine.

Cel-Sci Corporation (NYSE AMEX: CVM)with headquarters in Vienna, Va.,posted a net loss for Q2 2011, nearly six times deeper than in the second quarter of 2010.

Losses were $3.11 Million in the three-months quarter ended June 30, 2011 compared to $601,124 in 2010.

Revenue in the second quarter came entirely from grants and totaled a small sum of $77,403.

The company's expenses grew to $4.85 Million from $3.4 Million.

July 21, 2011

The largest biotech in the Baltimore-Washington area measured by market value said Benlysta is gaining momentum in net sales

After more than a decade of research, development, and waiting more than a year for a delayed FDA approval, Human Genome Sciences, Inc (NASDAQ: HGSI) finally has a drug on the market that it can consistently sell to the healthcare industry.

The Rockville, Md biotechnology company reported Benlysta net sales of $7.8 Million. $1.2 Million in additional sales were excluded due to non-delivery to healthcare providers prior to the release of second quarter financial results.

Increasing Lupus Drug Sales

June 27, 2011

The Chinese Biopharmaceutical Association held its annual event Sunday at the University System of Maryland, Shady Grove Campus in Rockville.

The 16th annual event for the association was represented by a large number of executives from China as well as the United States. The organization's members include scientists, attorneys, entrepreneurs and other professionals. More than four delegations in groups of ten or more attended the event, flying all the way from China.

June 16, 2011

Despite recession, several Maryland Biotechs turn a profit

Biotechnology firms have been reported to be hard hit by the recent recession; struggling to stay afloat amid a dearth of venture capital funding and and lack of new drugs selling on the market. The Biotech industry is often pigeonholed as frail, cash strapped and high risk; spending years on research to develop drugs but often ending with failure and bankruptcy.

But in Maryland it's a different story. Several biotech firms have achieved profitability for their full fiscal year and some of them for the first time in the midst of a troubled U.S. economy.

March 21, 2014

Washington, D.C.-based Vanda Pharmaceuticals Inc (NASDAQ:VNDA), has launched a couple of drugs and even recently put into place a television ad campaign. The company is now in need of extra space and will expand into an additional 8,600 square feet at its D.C. headquarters located at 2200 Pennsylvania Avenue.

Vanda will pay the landlord, Square 54 Office Owner LLC, and additional $381,000 for a 12 year and one month term lease beginning on September 1, 2014, although Vanda will get a nine month grace period.

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

March 13, 2014

Germantown, Maryland-based Intrexon Corporation (NYSE:XON) stock was recently upgraded by EVA Dimensions last week but that doesn’t explain yesterdays price surge of more than 10 percent for the company.

Intrexon was the third most price-trending stock on Google Finance yesterday, the stock price of the company increased more than 11.46 percent (+ $3.14) to close at $30.55 per share.

A few reasons that could have driven Intrexon’s stock price higher,

March 13, 2014

In late 2012 Sucampo Pharmaceuticals (NASDAQ: SCMP) received approval from the Food and Drug Administration (FDA)  to expand upon its gastrointestinal drug -- AMITIZA -- to treat people with opioid-induced constipation (OIC) in the United States.

With increasing competition from other biotechnology companies, that approval is keeping the Bethesda-based drug developer ahead of them and profitable, with a net income posted in 3 out of the last 4 quarters of 2013, including the most recent fourth quarter.

February 6, 2012

United Therapeutics Corporation (NASDAQ: UTHR)said it received notice from a generic drug manufacturer that it intends to release a remanufactured form of one of Silver Spring-based company's core drugs called Remodulin.

Sandoz Inc, submitted a Paragraph IV Certification Notice Letter which United Therapeutics received on February 3, 2012. The letter states that the company has sent an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) also in Silver Spring.

October 25, 2011

The Maryland biotech said increased loss was due to higher selling, general and administrative expenses

Rockville-based Human Genome Sciences, Inc. (Nasdaq: HGSI) which launched Benlysta -- the first Lupus Drug in 56 years -- reported full quarter sales of it first consumer product.

The biotechnology company that partnered with GlaxoSmithKline PLC (NYSE: GSK) for Benlysta development said U.S. gross sales of the drug amounted to $21.3 million; net sales of the product were $18.8 million. That compares with $7.8 million of Benlysta sales in second quarter of 2011 although product delivery was not at full strength.

August 8, 2011

biotechnology firm in Bethesda is taking on multiple matters to keep its revenue stream growing.

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), a biotechnology firm in Bethesda is taking on multiple matters to keep its revenue stream growing.

Chairman and Chief Executive Officer, Ryuji Ueno, M.D., Ph.D., Ph.D., said in a statement during its second quarter 2011, financial results that the company has filed a marketing application in the U.K. for approval of its drug lubiprostone to treat chronic idiopathic constipation.

August 4, 2011

Vanda Pharmaceuticals Inc., (NASDAQ: VNDA) which recently announced it would be moving its headquarters to 2200 Pennsylvania Avenue, N.W. in Washington, D.C., released disappointing financial results for the second quarter ended June 30, 2011.

Revenues plunged 28% to $14.9 Million in the six months ended June 30, 2011 from $20.7 Million at the end of June 30, 2010, a $5.78 Million difference.

A net loss of $1.2 Million was reported by the Rockville based company for the first half of the year.

July 26, 2011

Schizophrenia drug maker Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) said its Marketing Authorization Application (MAA) has been accepted by the European Medicines Agency.

The Rockville, Md biotechnology company which won a surprising approval for its Fanapt (Iloperidone) schizophrenia drug in May 2009 is trying to sell the oral version of the drug in the European Union.

July 19, 2011

Vienna based Cel-Sci Corporation (NYSE AMEX: CVM) said it has modified its licensing agreement with Israel based Teva Pharmaceutical Industries Ltd.

The agreement will now include eastern European country Croatia and the nation of Serbia in addition to the countries, Israel and Turkey.

The joint venture centers around Cel-Sci's experimental cancer treatment drug called Multikine. Pharmaceutical giant Teva will be responsible for marketing and fees associated with selling Multikine. Profits and revenue will be divided between Teva and Cel-sci.

July 19, 2011

The agreement could mean another merger and acquisition for the region

Another area based biotechnology company has partnered with a company on the other side of the country, a much larger company, far, far away from here.

This time it's Rockville based Micromet, Inc.

Micromet, Inc labels itself as a biopharmaceutical company focused on finding treatments for cancer through commercialization of innovative antibody based therapies. The company traces its root back to 1993 in Munich, Germany where a small group of scientists set upon treating cancer via T cell based therapies.

July 11, 2011

Press Release

"Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt(TM) in Mexico

June 30, 2011

The Brilliant Achievement Award was presented to Human Genome Sciences CEO Thomas Watkins at the 16th Annual Chinese Biopharmaceutical Association Conference.

"The CBA Brilliant Achievement Award is given to honor outstanding individuals who have made significant contributions to science, technology, or business development in the bio pharmaceutical fields." said Zhifeng Long, Ph.D. Chair of the Conference Organizing Committee who was also honored and name President of the CBA for 2011 - 2012.